两性霉素B与伏立康唑治疗急性淋巴细胞白血病合并侵入性真菌感染的临床对比

摘要

Objective To compare the clinical effects and securities of amphotericin B and vori-conazole in the treatment of patients with acute lymphoblastic leukemia complicated with invasive fungal infection. Methods Ninety-six patients suitable for the experiment were divided into amphotericin B group(n = 40)and voriconazole group(n = 56),and the clinical effects and securities between the two groups tvere compared. Results The total efficiency rate in amphotericin B group was 77. 5%(31 / 40), and the rate of drug-related adverse event was 62. 5%(25 / 40). However,the total efficiency rate was 92. 8%(52 / 56),and the incidence of drug-related adverse event was 16. 1%(9 / 56)in voriconazole group,there were significant differences between the two groups(P < 0. 05). Conclusions Amphoteri-cin B and voriconazole are both effective for patients with acute lymphoblastic leukemia complicated with invasive fungal infection,and voriconazole has better clinical effects and lower adverse event rate.%目的：评价两性霉素 B 与伏立康唑两种抗真菌药物在急性淋巴细胞白血病合并侵入性真菌感染治疗中的疗效及安全性。方法96例急性淋巴细胞白血病并发侵袭性细菌感染患者，根据不同抗真菌治疗药物分成两组，两性霉素 B 治疗组（n =40）和伏立康唑治疗组（n =56），观察两组患者的临床疗效和不良反应。结果两性霉素 B 组的总有效率为77.5%（31/40），药物相关的不良反应发生率为62.5%（25/40）；伏立康唑组的总有效率为92.8%（52/56），不良反应发生率为16.1%（9/56）；两组有效率和不良反应发生率比较差异均有统计学意义（P <0.05）。结论两种药物对急性淋巴细胞白血病合并侵袭性真菌感染的患者均有效，且伏立康唑治疗血液系统恶性肿瘤并发侵袭性真菌感染的疗效更加确切，不良反应发生率更低。